NeuBase Therapeutics down on plans to halt development of pre-clinical programs

NeuBase Therapeutics

03/08/2023 16:02

** Shares of biotech co NeuBase Therapeutics Inc  NBSE.O 
fall 24.2% to $0.93
    ** Co plans to halt further development of its programs and
to conduct exploration of strategic alternatives
    ** The company's pipeline includes five pre-clinical trials
for different indications 
    ** Adds its board has not set a timetable for completion of
this evaluation process, and it may include, but are not limited
to, an acquisition, merger, business combination, or other
transaction 
    ** Including session's fall, stock down 75.63% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))